Patent ID: 8629098

Claim:
An artificial antigen-presenting cell (aAPC) composition comprising polymeric nano- or microparticles, at least one cytokine encapsulated in or incorporated into the nano- or microparticles, coupling agents bound to or incorporated into the surface of the nano- or microparticles, at least one T cell receptor activator bound to the nano- or microparticles, and at least one co-stimulatory molecule bound to the nano- or microparticles, wherein the at least one cytokine is selected from the group consisting of granulocyte macrophage colony stimulating factor (GM-CSF), tumor necrosis factor alpha (TNFα), tumor necrosis factor beta (TNFβ), macrophage colon stimulating factor (M-CSF), interleukin-1 (IL-1), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-21 (IL-21), interferon alpha (IFNα), interferon beta (IFNβ), interferon gamma (IFNγ), and IGIF, and variants and fragments thereof, wherein the at least one T cell receptor activator comprises MHC molecules bound to peptide antigens, or wherein the at least one co-stimulatory molecule is selected from the group consisting of CD7, B7-1 (CD80), B7-2 (CD86), PD-L1, PD-L2, 4-1BBL, OX40L, inducible co-stimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD2, CD5, CD9, CD30L, CD40, CD70, CD83, HLA-G, MICA, MICB, HVEM, lymphotoxin beta receptor, 3/TR6, ILT3, ILT4, HVEM, a ligand that specifically binds with B7-H3, a ligand that specifically binds with CD83 and antibodies that specifically bind with Toll ligand receptor, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C and B7-H3 and variants and fragments thereof.